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ABSTRACT 
Glycosaminoglycan  synthesis  and  secretion  by  primate  arterial  smooth  muscle 
have  been  examined  in  cell  culture.  Mass  cultures  of diploid  primate  arterial 
smooth muscle cells were either double labeled with [ssS]sulfate and [3H]acetate or 
single  labeled  with  [SH]glucosamine  for  24  h  and  glycosaminoglycans  were 
extracted  and  isolated  from  the  culture  medium.  Incorporation  of  labeled 
precursors  into  glycosaminoglycan  was  maximal  during  stationary  phase  of 
smooth  muscle  cell  growth  in  culture  and  reduced,  but  not  eliminated  during 
logarithmic  growth.  The  glycosaminoglyeans synthesized  and  secreted  into  the 
culture medium were characterized by differential susceptibility to glycosaminogly- 
can-degradative  enzymes  and  by  cellulose  acetate  electrophoresis.  Both  assay 
procedures indicate that cultured primate arterial smooth muscle cells synthesize 
principally dermatan  sulfate (60%-80% of total), chondroitin sulfate A  and/or C 
(10%-20% of total) and little or no hyaluronic acid (0%-5% of total). This pattern 
of  glycosaminoglycan  formation  differed  significantly  from  that  exhibited  by 
isologous skin  fibroblasts cultured under identical conditions. Dermal fibroblasts 
synthesize and  secrete primarily hyaluronic acid  (50%-60%  of total) with  lesser 
amounts of dermatan sulfate (10%-20% of total) and chondroitin sulfate A and/or 
C (10%-20% of total). These results indicate that differences exist in proteoglycan 
metabolism  between  these  two  connective  tissue-producing  cells  in  vitro,  and 
suggest  that  the  observed  pattern  of  in  vitro  glycosaminoglycan  synthesis  by 
primate arterial smooth muscle cells may be characteristic for this cell type and not 
a general response to conditions of cell culture. 
Although  proteoglycans are known  to be impor- 
tant constituents of the connective tissues of artery 
walls (3, 4,  12, 25, 26, 43, 63, 64), knowledge  of 
their cellular source and metabolism is limited.  In 
the  accompanying  study  (63),  we  demonstrate 
that the smooth muscle  of the intima and media 
of primate  arteries  is  surrounded  by  numerous 
proteoglycan  granules  and  suggest  that  the 
smooth muscle cell is responsible  for the synthesis 
and  secretion  of these  connective  tissue  compo- 
nents.  Other  studies  have  demonstrated  that 
arterial smooth muscle cells are capable of synthe- 
sizing and secreting  collagen  and elastic fibers in 
vivo (51)  and  in  vitro (48,  49)  confirming their 
connective  tissue-synthetic  capacity,  but  this 
cell's ability to form proteoglycans has  not been 
definitively established. 
In  the  present  study,  we  have  examined  the 
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to  synthesize  and  secrete  glycosaminoglycans t  in 
vitro by addressing the following questions: (a) do 
primate  arterial  smooth  muscle  cells  synthesize 
and secrete glycosaminoglycans in vitro? (b) if so, 
what types of glycosaminoglycan are formed, and 
in  what  relative  amounts?  (c)  does  the  rate  of 
synthesis  of these  macromolecules  change during 
different stages of growth in culture of the arterial 
smooth  muscle?  and  (d)  is  the  in  vitro pattern  of 
glycosaminoglycan  synthesis  by  primate  arterial 
smooth  muscle  cells  similar  to  or  different  from 
other  connective  tissue-producing  mesenchymal 
cells in culture,  such as skin fibroblasts? 
MATERIALS  AND  METHODS 
Preparation  of Smooth Muscle and 
Fibroblast Cell Cultures 
Arterial smooth muscle cell cultures were established 
by the method of Ross (48, 49). Strips of intimal medial 
tissue  from  the  thoracic  aorta  of  l-2-yr  old  pigtail 
monkeys  (Macaca nemestrina) were  r  in  the 
Dulbecco-Vogt modification of Eagle's minimal medium 
supplemented with either 5% or 10% homologous serum. 
Cells were allowed to grow to confluency, at which time 
they were trypsinized and passed. Cells were replated at a 
density of 7.0  ￿  10' cells/ml in 250-ml Falcon flasks in 
10 ml of medium supplemented with 5% pooled homolo- 
gous  serum  and  allowed  to  grow  to  confluency in  an 
atmosphere of 5% CO2 and 95% air at 37~  Cultures in 
the second to sixth passages were used in all experiments. 
Previous  electron  microscope  studies  of  cultures  pre- 
pared in this manner at saturation density have revealed 
that all the cells have the ultrastructural characteristics of 
smooth muscle (49). 
Arterial smooth muscle cell growth curves were estab- 
lished by maintaining parallel cultures in different con- 
centrations of serum  as  previously described (49,  50). 
Equal numbers ( 9 ￿  10  ~ cells) of trypsin-treated smooth 
muscle cells were plated, with a  Cornwall syringe, into 
60-ram Falcon plastic petri dishes (Falcon Plastics, Div. 
of B.-D.  Laboratories,  Los  Angeles, Calif.) and  main- 
tained  in  medium  containing  1%  pooled  homologous 
serum for 7 days (medium changed three times a week). 
On  day  7,  one-half of  the  cultures  received  medium 
containing 5% pooled homologous serum while the other 
half were transferred to a medium containing no serum. 
t This  study  uses  extraction  procedures  which  remove 
and isolate the glycosaminoglycan portion of the proteo- 
glycan for analysis. Although the protein moiety of the 
proteoglycan was not analyzed, it can be assumed that 
analysis of glycosaminoglycan synthesis reflects proteo- 
glycan synthesis by these cells. 
Sufficient numbers of dishes of cells were maintained to 
determined a  growth curve for a  period of at least  16 
days.  Cell  numbers were determined by counting in a 
Fuchs-Rosenthal chamber.  Mean  and  standard  errors 
were calculated for each point in the growth curve. 
Skin fibroblast cultures were established from abdom- 
inal  skin  from  the  same donor  animal.  Pieces of skin 
were minced into 2-ram squares and treated in the same 
manner as the smooth muscle explants. Subsequent to 
trypsinization, fibroblasts were grown in either 5% (M42) 
or 4% (M52) homologous serum. 
Measurement of Glycosaminoglycan 
Synthesis and Secretion 
Confluent cultures were either single labeled with 20 
.Ci[SH]glucosamine per flask or double labeled with 20 
,Ci [asS]sulfate,  carrier free, and 20 ,Ci [SH]acetate per 
flask  (New  England Nuclear,  Boston, Mass.) for 24 h. 
Eight  flasks  comprised  each  experiment  and  yielded 
between  12  and  30  ￿  106  cells.  After  labeling,  the 
medium was removed and cell counts were determined as 
previously described. The labeled medium was extracted 
for glycosaminoglycans by the procedure  of Nameroff 
and  Holtzer  (44).  Briefly,  this  procedure  consists  of 
boiling  the  samples  for  5  min,  followed  by  pronase 
digestion (0.5  mg/ml in 0.2 M Tris-HCI buffer, pH 8.0) 
for  18 h  at 60~  Ice-cold tricholoroacetic acid (TCA) 
was  added  to  a  final  concentration  of  10%  and  the 
precipitates were removed by centrifugation. The super- 
nates were exhaustively dialyzed at 4~  initially against 
0.01  M  solutions of the  appropriately  unlabeled com- 
pounds and finally against distilled H 20. The isotopically 
labeled material was concentrated by contact dessication 
(Aquacide, Calbiochem, San Diego, Calif.) and portions 
were taken for enzyme-subtraction digestion assays and 
for electrophoresis. 
To eliminate the possibility of nonspecific trapping of 
the isotope(s) in the culture medium, as well as to check 
for  possible  cell-free  synthesis (i.e.  sulfation),  parallel 
flasks  containing  culture  medium  with  no  cells  were 
labeled and the medium was extracted for glycosamino- 
glycans as previously described. 
Measurement of the Rate of 
Glycosaminoglycan  Synthesis During 
Log and Stationary Phase of Growth 
To  determine  whether  glycosaminoglycan  synthesis 
occurred  in both dividing and nondividing cell popula- 
tions, culture dishes were double labeled with [ssS]sulfate 
and [all]acetate (20 t~Ci/dish) for 48 h on days 5, 7,  10, 
12, and 17 of the growth curve. The culture medium from 
each of these time intervals was extracted for glycosami- 
noglycans as previously described and specific activities 
were determined (dpm/10' cells). 
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ENZYME  DIGESTION-SUBTRACTION  METHOD~ 
To examine the typas of glycosaminoglycan synthesized 
and  secreted  by arterial smooth muscle cells in cultu~, 
we employed an assay system  based  upon  the differen- 
tial susceptibility  of different glycosaminoglycans to spe- 
cific polysaccharidascs according to the scheme of Toole 
and Gross (60).  Equal porti.ons (1.0  ml) of isotopically 
labeled  TCA-soluble,  nondialyzahle  material  isolated 
from the medium were incubated with each of the fol- 
lowing enzymes at  37~  (a) 40 ,g of leech hyaluroni- 
dasc (Biotrics, Inc., Boston, Mass.) in MclIvaine's stan- 
dard buffer (14), pH 5.4, each hour for 5 h; (b) 1,000 IU 
of  testicular  hyaluronidasr  (Miles  Laboratories,  Inc., 
Kankaker  IU.) in sodium acetate buffer (52) pH 5.4, for 
24 h followed by another  1,000 IU of fresh  enzyme for 
48 h; (c) 0.5 U of chondroitinasr ABC (Miles) in enriched 
Tris buffer (52), pH 8.0, for 24 h followed by another 0.5 
U of fresh enzyme for 48 h. Controls consisted of samples 
plus appropriate buffers without enzymes. 
After incubation in all experiments, equal aliquots (1.0 
ml) of the digestion products were separated on a column 
of Sephadex G-25, fine (2.5 ￿  90 cm), collected as 3.0-ml 
fractions,  and  assayed  for  radioactivity  with  Aquasol 
(New England Nuclear) in a Packard Tri-Carb scintilla- 
tion counter.  By determining the percentage of activity 
retarded on G-25 as a function of total activity applied to 
the column, it is  possible  to obtain  an estimate of the 
types of glycosaminoglycans present  in the sample (A. 
Dorfman,  personal  communication).  Using 
[aH]glucosamine  or [aHlaceta~  as precursors,  the per- 
centage of activity retarded  in  the leech hyaluronidase 
digests serves an an estimate of the amount of hyaluronic 
acid  present  since  this  enzyme  specifically  degrades 
hyaluronic acid (A. Balazs, personal communication). By 
using  [~S]sulfate  as a  precursor,  the  retarded  fraction 
from  the  testicular  hyaluronidase  digest  provides  an 
estimate of the amount of chondroitin sulfate A and C in 
the sample (52). Subtraction of the amount of 86S activity 
retarded in the testicular hyaluronidase digests  from the 
ssS activity retarded  in the chondroitinase ABC digests 
provides an estimate of the amount of dermatan sulfate 
present,  since both of these enzymes degrade chondroitin 
sulfate  A  and  C  but  only  chondroitinase  ABC  fully 
degrades dermatan  sulfate (52). The  activities of these 
enzymes were checked by  incubating them with glycos- 
aminoglyean  standards  (Seikagaku  Fine  Biochemicals, 
Tokyo, Japan) and by performing uronic acid determina- 
tions (10) on the digestion products collected as 3.0-ml 
fractions from Sephadex G25. 
CELLULOSE  ACETATE  ELECTROPHORESIS:  To 
confirm the results  obtained by using the enzyme diges- 
tion subtraction  method, additional aliquots of isotopi- 
cally labeled  nondialyzable,  TCA-soluble material  iso- 
lated from the culture medium were mixed with 50 ~.g of 
standard  hyaluronic  acid,  chondroitin  sulfate  C,  and 
dermatan  sulfate, and electrophorescd on cellulose ace- 
tate paper (Geiman Instrument Co., Ann Arbor, Mich.) 
in 0.1 M pyridine-formate buffer, pH 3.0, at 100 V for 60 
min at  room temperature  (44).  After drying, the strips 
were stained  with 0. i % toluidine blue in 30% methanol to 
identify  the position of the carriers. The strips were air 
dried, cut into 0.5-cm fractions, and assayed  for radioac- 
tivity using  Aquasol (New England Nuclear) in a  Pac- 
kard Tri-Carb liquid scintillation counter. 
RESULTS 
Proteoglycan Synthesis and Secretion 
by Primate A rterial Smooth Muscle 
Cells in  Vitro 
Mass cultures of primate arterial smooth muscle 
cells  incorporated  [ssS]sulfate,  [SH]acetate,  and 
[~H]glucosamine into TCA-soluble, nondialyzable 
material  at saturation  density (Table  I). Since the 
majority of the activity was present in the medium 
(~85%)  as  compared  to  the  cell  layer  (~15%), 
only the  labeled  medium  was  analyzed  for newly 
synthesized  glycosaminoglycans.  Virtually  all the 
activity present  in  the  TCA-soluble  material  iso- 
lated from control flasks (medium  incubated  with 
isotopic  precursors  in  the  absence  of  cells)  was 
dialyzable. 
To obtain an estimate of the types of glycosami- 
noglycans present in these medium isolates, paral- 
lel aliquots were digested with glycosaminoglycan- 
specific  degradative  enzymes  and  the  digestion 
products  separated  on  Sephadex  G-25  columns. 
Approximately 95%  of the activity present  in the 
[SH]acetate- and  [3H]glucosamine-labeled  isolates 
emerged in the void volume after leech hyaluroni- 
dase  digestion,  indicating  minimal  degradation 
(Fig.  1).  10-20%  of the  [ssS]sulfate  activity  and 
slightly less Jail]acetate or [SH]glucosamine activ- 
ity emerged slightly behind the void volume in the 
testicular  hyaluronidase  digests, indicating partial 
degradation  (Fig.  2).  80-90%  of the  [asS]sulfate 
activity and 60-80% of the [SH]acetate or [SH]glu- 
cosamine activity in the medium isolates emerged 
as  a  distinct second peak  behind  the void volume 
after chondroitinase ABC digestion, indicating ex- 
tensive degradation  (Fig. 3). 
By  calculating  the  percentage  of  activity  re- 
tarded  on  Sephadex  G-25  columns  in each digest 
as a function of total activity applied to the column 
and  using  the  enzyme  digestion  subtraction 
method,  we  are  able  to  make  the  following esti- 
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Incorporation of [seS]Sulfate, [ell]Acetate, and [SH]Glucosamine into TCA-Soluble, Nondialyzable Material 
Isolated from the Medium of Primate Arterial Smooth  Muscle Cell Cultures 
[see]Sulfate*  [ell]Acetate*  [SH]Glucosamine* 
Experiment no.  Medium  Cell Layer  Medium  Cell Layer  Medium  Cell Layer 
M =sTe  63,700  2,100  .... 
MeeTs  45,145  2,369  .... 
M=~T.  46,938  2,367  .... 
M s,T =  45,016  7,290  44,925  5,705  --  -- 
M.Ts  14,574  1,807  37,198  9,101  --  -- 
MeeT=  28,197  1,458  239,572  30,851  --  -- 
Ms,Ts  25,558  1,473  130,833  13,456  --  -- 
MssTs  ....  48,071  4,015 
MssTs  ....  239,335  17,553 
* dpm/lO  e cells. 
12,000] 
~  ~'A  Control 
9~176176  1  g  En.~ 
10  14  18  22  26 
Froction  No, 
FIGURE 1  Eiution pattern  from Sephadex 0-25 of the 
products from the digestion with leech hyaluronidase of 
[=H]glucosamine-  (0  0)  and  [=H]acetate- 
(O  ........ O)  labeled  TCA-soluble,  nondialyzable  ma- 
terial  isolated  from  the  medium  of  primate  arterial 
smooth muscle cells in vitro. Approximately 95% of the 
activity present  in  the  SH-labeled  isolates emerged  in 
the  void  volume,  indicating  minimal  degradation  and 
small amounts of hyaluronic acid present in the sample. 
mates  of the types  of glycosaminoglycans synthe- 
sized  and  secreted  by  primate  arterial  smooth 
muscle  cells  in  vitro:  hyaluronic  acid  (0  5%); 
chondroitin  sulfate A  and/or C  (10-20%); derma- 
tan sulfate (60-80%);  other sulfated glycosamino- 
glycans (10% or less). These values represent mean 
ranges  in four separate experiments. 
To  verify  this  assay  for  glycosaminoglycan 
identification,  parallel  portions  of labeled  TCA- 
soluble,  nondialyzable  material  isolated  from  the 
smooth  muscle  cell culture  medium  were  charac- 
4000-  ,*, 
30C0-  ~I\'~  Control 
2000-  ,  , 
Q. 
~  4000- 
NX)O-  b~  I  /  ~  Enzyme 
/  /./  \' 
I~I  //  '~ 
1C)'  '  '14'  '  '  l'B'  '  '22'  '  '2'6 
Froction No 
FIGURE  2  Elution pattern from Sephadex 0-25 of the 
products from the digestion with testicular hyaluronidase 
of  [eeS]sulfate-  (O  0)  and  [eH]acetate- 
(O  ........  O)  labeled  TCA-soluble,  nondialyzable  ma- 
terial  isolated  from  the  medium  of  primate  arterial 
smooth muscle cells in vitro.  10-20% of the ['S]sulfate 
activity and  slightly  less  [ell]acetate  activity emerged 
slightly  behind the void volume, indicating that there are 
moderate  amounts  of chondroitin  sulfate  A  and/or  C 
(10-20% of total) present in the sample. 
terized by cellulose acetate electrophoresis against 
known  glycosaminoglycan  standards.  By spotting 
approximately  20  #g  of  each  standard,  it  was 
possible  to  obtain  clear  separation  of hyaluronic 
acid, dermatan  sulfate, and chondroitin sulfates A 
and/or C  (chondroitin sulfate A  migrates together 
with chondroitin  sulfate C  and it is not possible to 
separate  these  isomers  by  using  the conditions  of 
electrophoresis  in  this  study).  The  major  peak  of 
radioactivity in all electrophoresed portions corre- 
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of the total activity),  with lesser peaks  associated 
with the chondroitin sulfate C  standard  (10-40%) 
and  several  minor  peaks  which  migrated  behind 
dermatan  sulfate (0-18%) (Fig.  4). 
Although there is slight variation in the relative 
amounts  of  glycosaminoglycans  synthesized  and 
secreted by arterial smooth muscle cells in vitro as 
determined  by  these  two  assay  systems,  both 
assays were reproducible in several different exper- 
iments  and  indicate  that  the  major glycosamino- 
glycan  synthesized  and  secreted  by  these  cells  is 
dermatan  sulfate  (at  least 60%  of total).  Further- 
more,  these  results  indicate that these cells make 
little  or  no  hyaluronic  acid  under  the  culture 
conditions used  in these experiments. 
Synthesis and Secretion  of 
Giycosaminoglycans  by Primate Arterial 
Smooth  Muscle Cells During Log and 
Stationary  Phases of Growth 
To  determine  whether  glycosaminoglycan  syn- 
thesis  could  occur  in  both  actively  growing  and 
quiescent cell populations,  arterial smooth muscle 
4ooo-  !~ 
Control 
2000- 
4000~  ................  , . 
3000  ~ 
Enzyme  :',  f',\  2ooo.  ;  , 
/  , 
looo.  /  .  4, 
10  14  18  22  26 
Fraction  No. 
FIGURE 3  Elution pattern from Sephadex G-25 of the 
products from the digestion with chondroitinase ABC of 
['6S]sulfate-  (0----------0) and  [SH]aoetate  (O  ........ O) 
labeled  TCA-soluble,  nondialyzable  material  isolated 
from the medium of primate arterial smooth muscle cells 
in vitro. 80-90% of the [ssS]sulfate activity and 60-80% 
of  the  [all]acetate  activity  emerged  in  the  retarded 
fraction,  indicating large  amounts of dermatan  sulfate 
present in the sample. 
FIGURE  4  Cellulose  acetate  electrophoresis  of  [ssS]- 
sulfate-  and  [SH]acetate-labeled  TCA-soluble,  nondi- 
alyzable material isolated from the medium of primate 
arterial smooth muscle cells in vitro. Electrophoresis of 
standard  glycosaminoglycans (HA  =  hyaluronic  acid; 
DS  =  dermatan sulfate; CSC  =  chondroitin sulfate C) 
is  superimposed  at  the  top  of  the  figure.  The  major 
peaks  of  radioactivity  in  all  electrophoresed  aliquots 
corresponded to the dermatan sulfate standard with less 
activity associated with the chondroitin sulfate C  stan- 
dard.  Minimal  [all]acetate  activity  cor 
with the hyaluronic acid standard. 
TABLE !I 
Incorporation of[SH]Acetate and [asS]Sulfate into TCA-Soluble, Nondialyzable Material by Cultured Primate 
Arterial Smooth Muscle Cells during Stationary and Log Growth 
I% Serum  0% Serum  5% Serum 
Labeling period  ["SlSulfate*  ['H]Acetate*  p'S]Sulfatc*  [SH]Acetate*  [=*S]Sulfate*  13H]Acetate  * 
5-7  1,510  20,900  .... 
7-9  --  --  1,880  25,100  1,010  20,0660 
10-12  --  --  1,930  19,990  660  7,540 
12-14  --  --  2,230  26,790  700  10,580 
17-19  --  --  1,850  17,530  430  3,820 
* dpm/10' cells. 
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[seS]sulfate  and  [SH]acetate  during log  and  sta- 
tionary phases of growth, and the specific  activity 
(dpm/10  e cells) of the TCA-soluble, nondialyzable 
material in the medium isolates was determined. 
Data  in Table  I1  demonstrate that  the  synthesis 
and secretion is maximal during stationary phases 
of  growth  and  decreases  to  approximately one- 
third the normal value by 3-4 days after the cells 
have been stimulated to divide by the addition of 
5% serum (Fig. 5). This reduced rate of synthesis 
was evident throughout the culture period as long 
as the cells grew logarithmically. 
The  types  of  glycosaminoglycans synthesized 
during these different phases of growth were  not 
determined  because  the  radioactivity in  the  me- 
dium isolates was too low for analysis. Additional 
experiments using a  greater  number of cells  are 
currently in progress to investigate the pattern of 
glycosaminoglycan synthesis  by  arterial  smooth 
10 s  - 
\  10  s  /•5% 
serum 
......  ..... 
~o" l~'~  "~, ￿9  L'/*,~-  '~  ~,=  ......... 
2  4  6  a  101z,4~,azo 
Days  in  Culture 
FIGURE  5  Growth  curve  of  primate  arterial  smooth 
muscle cells in vitro. Cultures were initially maintained in 
a  1%  homologous serum containing medium and then 
transferred on day 7 (arrow) to medium containing either 
no  serum  (  ....... )  or  5%  homologous serum (  ). 
Cultures  were double  labeled with [35S]sulfate and 
[all]acetate for 48 h on days 5, 7, 10, 12, and 17 and the 
medium was extracted for glycosaminoglycans  at each of 
these times (see Table II). 
muscle cells during their different growth phases in 
culture. 
Pattern of Giycosaminoglycan Synthesis 
by Arterial Smooth Muscle  Cells vs. 
Skin Fibroblasts 
To determine whether the  observed pattern of 
glycosaminoglycan synthesis was characteristic of 
arterial  smooth  muscle  cells  or  represented  a 
general  response  displayed  by  other  types  of 
connective tissue cells in culture, we compared the 
pattern  of  glycosaminoglycan synthesis  between 
arterial smooth muscle cells and dermal fibroblasts 
derived from  the same donor under the identical 
culture conditions. 
Using  [SH]acetate  and  [35S]sulfate  as  precur- 
sors,  the  TCA-soluble,  nondialyzable  material 
isolated  from  the  medium of skin fibroblast cul- 
tures contained considerably more [SH]acetate ac- 
tivity but less [asS]sulfate activity than similar ma- 
terial isolated from the smooth muscle cell culture 
medium  (Table  III).  Approximately 60%  of the 
[SH]acetate  activity in the  skin fibroblast culture 
medium  was  retarded  on  Sephadex  G-25  after 
leech  hyaluronidase digestion (Fig. 6).  Testicular 
hyaluronidase caused  approximately 72%  of the 
[SH]acetate activity in the medium isolates to elute 
in the retarded fractions (Fig. 7), while 85% of the 
[SH]acetate activity was retarded after condroitin- 
ase ABC digestion (Fig. 8). It should be noted that 
testicular hyaluronidase and chondroitinase ABC 
degrade  hyaluronic acid in addition to their spe- 
cific chondroitin sulfate isomers (52). Using the en- 
zyme digestion subtratction method, we are able to 
make the following estimates as to the types of gly- 
cosaminoglycans synthesized and secreted by skin 
fibroblasts  in  vitro:  hyaluronic  acid  (50-60%); 
chondroitin sulfate A and/or C (10-20%); derma- 
tan sulfate (10-20%); other (10-20%). This pattern 
of  in  vitro  glycosaminoglycan synthesis by  skin 
TABLE  Iii 
Comparison of the Incorporation of [s~S]Sulfate  and [sH]A cetate into TCA-Soluble, Nondialyzable Material by 
Primate Arterial Smooth Muscle Cells and Skin Fibroblusts In  Vitro 
Smooth muscle  Skin fibroblast 
Experiment no.  {~S]Sulfate*  [all]Acetate*  [ssSlSulfate*  [SHlAcetate* 
M,,T,  7.026  66.029  1,768  184.335 
M ,,T,  4,342  34,209  2,820  197,514 
M a  2"l'z  14.574  37.198  10,752  120,540 
* dpm/10 e cells. 
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FIGURE 6  Elution pattern  from Sephadex G-25 of the 
products from the digestion with leech hyaluronidase of 
['H]acetate-labeled,  TCA-soluble,  nondialyzable  mate- 
rial isolated from the medium of primate skin  fibroblast 
cultures. Approximately 60% of the ['H]acetate activity 
was  eluted  in  the  retarded  fractions,  indicating  that  a 
significant amount  of the sample contained hyaluronic 
acid. 
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FIGURE 7  Elution pattern  from Sephadex G-25 of the 
products from the digestion with testicular hyaluronidase 
of ['H]acetate-labeled TCA-soluble, nondialyzable mate- 
rial isolated from the medium of skin fibroblast cultures. 
This digestion resulted  in retarding 72% of the [SH]ace- 
tate  activity, indicating that  approximately  12%  of the 
total  glycosaminoglycans  present  in  the  sample  was 
chondroitin sulfate A and/or C. 
fibroblasts  is  distinctly  different  from  that  of 
arterial  smooth  muscle cells. 
Cellulose  acetate  electrophoresis  of  medium 
isolated  from  skin  fibroblast  and  arterial  smooth 
muscle cell cultures confirmed this difference (Fig. 
9). Approximately 60-70% of the [SH]acetate label 
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FIGURE 8  Elution pattern  from Sephadex G-25  of the 
products from the digestion with chondroitinase ABC of 
['H]acetate-labeled,  TCA-soluble, nondialyzable  mate- 
rial isolated from the medium of skin fibroblast cultures. 
An  additional  13%  of  the  ['H]acetate  activity  was 
retardod  after  this digestion,  indicating  approximately 
equal amounts of dermatan sulfate and chondroitin sub 
fate A and/or C present in the sample. 
FIGURE 9  Comparison  of the cellulose acetate electro- 
phoretic  pattern  of  [all]acetate-labeled,  TCA-soluble, 
nondialyzable  material  isolated  from  the  medium  of 
primate arterial smooth muscle cells and skin fibroblasts 
in vitro. Electrophoresis of standard glycosaminoglycans 
(HA  = hyaluronic acid; DA  = dermatan sulfate; CSC = 
chondroitin sulfate C) is superimposed at the top of the 
figure.  The  patterns  for  the  two cell types  are  clearly 
different and confirm the results  of the enzyme digestion 
subtraction  assay. 
was  concentrated  in  the  hyaluronic  acid  band  in 
medium  isolates  derived  from  skin  fibroblasts, 
while 0-4% of the label was present in this band in 
medium  isolates  from  the  smooth  muscle  cell 
WIGHT AND ROSS  Proteoglycans  in Primate Arteries.  11  681 cultures. On the other hand, only 3-5% of the total 
[SH]acetate activity present in the medium isolates 
from  skin fibroblast euRures comigrated with the 
dermatan  sulfate  band  from  medium  isolates of 
arterial smooth muscle cultures. Medium isolates 
from the fibroblast cultures contained only 2-3% 
of  the  [+H]acetate  activity  associated  with  the 
chondroitin  sulfate  A/C  standard,  while smooth 
muscle  medium  isolates  contained  10-20%  of 
total  [SH]acetate  activity  associated  with  this 
band. 
DISCUSSION 
Evidence for Glycosaminoglycan 
Synthesis  and Secretion  In  Vitro 
In the present study, we have demonstrated that 
cell cultures  of primate  arterial  smooth  muscle, 
prepared  from  l-2-yr  old  pigtail  monkey  (M. 
nemestrina) thoracic aortas synthesize and secrete 
significant quantities of sulfated glycosaminogly- 
cans  into  the  culture  medium.  The  finding  that 
approximately  90%  of  the  [ssS]sulfate-labeled 
TCA-soluble,  nondialyzable  material  isolated 
from the  medium  of these cultures was degraded 
by chondroitinase ABC indicates that the majority 
of  the  [86S]sulfate  was  incorporated  into  newly 
synthesized  glycosaminoglycans.  Approximately 
the  same  percentage  of [3sS]sulfate activity was 
associated with standard sulfated glycosaminogly- 
cans when  the  medium  isolates were subjected to 
electrophoresis,  confirming  the  results  obtained 
after chondroitinase ABC digestion and indicating 
that  sulfate  is  a  relatively specific precursor  for 
examination  of  sulfated  glycosaminoglycan syn- 
thesis by these cells. Whether the remaining  10% 
of  the  35S  label  was  present  in  chondroitinase 
ABC-resistant  glycosaminoglycans (heparan  sul- 
fate  and/or  keratosulfate),  or  incorporated  into 
other  macromolecules  such  as  sulfated  giyco- 
proteins (55), was not determined in this study. 
The  incorporation of [SH]acetate and  [SH]glu- 
cosamine  into  TCA-soluble,  nondialyzable  ma- 
terial isolated from the medium of these cultures 
and  the  subsequent  degradation  of  this  labeled 
material by chondroitinase ABC  further  indicate 
that  total glycosaminoglycan synthesis occurred, 
and  not  merely  sulfation  of pre-existing nonsul- 
fated  glycosaminoglycans (19,  30,  47,  58).  The 
observation that 60-80%  of the isolated [SH]ace- 
tate and  [SH]glucosamine activity in the medium 
coelectrophoresed  with  sulfated  glycosaminogly- 
can  standards  provides  further  support  for  this 
conclusion. 
Our  data  further  demonstrate  that  cultures  in 
logarithmic growth continue to synthesize glycos- 
aminoglycans, although  at  a  reduced  rate. These 
observations suggest that both dividing and nondi- 
riding cells synthesize and secrete glycosaminogly- 
cans  and  support  previous  studies  of  in  vitro 
glycosaminoglycan synthesis by corneal fibroblasts 
(7) and chondrocytes (6, 28, 29, 46). However, we 
did not determine the percentage of cells actively 
dividing, hence it is possible that the lower rate of 
synthesis during  log growth  reflects synthesis by 
quiescent  cells  that  are  not  synthesizing  DNA. 
Further studies would be necessary to exclude this 
possibility. 
Correlation of In  Vitro Pattern of 
Glycosaminoglycan Synthesis  with 
In  Vivo Observations 
The  observation  that  cultured  primate arterial 
smooth  muscle cells form  principally one type of 
sulfated glycosaminoglycan, dermatan sulfate, and 
lesser amounts of chondroitin sulfate A  and/or C 
is  of interest,  because  it  has  been  reported  that 
dermatan  sulfate  comprises  only  10-20%  of the 
total glycosaminoglycans present  in  artery  walls, 
whereas chondroitin sulfate A  and/or C  are pres- 
ent in much greater amounts (3,  9,  12,  16, 21, 25, 
26, 43, 53). There are several possible explanations 
for this apparent discrepancy. It is conceivable that 
the in vitro pattern of synthesis may be a response 
by the  smooth  muscle cells to the special condi- 
tions  of cell  culture,  since  a  variety  of  culture 
conditions are known  to exert different effects on 
glycosaminoglycan synthesis by other cell types (8, 
32,  36,  57).  Dermatan sulfate increases markedly 
in  arteries  that  develop  intimal  lesions  resulting 
from trauma (16) or after extensive lipid infiltra- 
tion (27).  These observations suggest that derma- 
tan sulfate synthesis may be a response by arterial 
smooth  muscle cells to some form of mechanical 
or  chemical  stress.  On  the  other  hand,  since 
experimentally  induced  arterial  intimal  hyper- 
plasia is characterized by extensive focal smooth 
muscle  proliferation, it  is  also  possible that  the 
culture conditions in which cells are rapidly prolif- 
erating  are  analagous  to  in  vivo  intimal  hyper- 
plasia. Thus,  the pattern of in vitro glycosamino- 
glycan synthesis may be a characteristic of prolif- 
erating cells. 
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noglycan synthesis reflects the particular state of 
development of the  arterial smooth  muscle cells. 
For example, it is well documented that  in  some 
developmental systems,  such  as  cornea  (37,  62), 
cartilage (24, 35, 41, 44, 54, 59), and heart (13, 31), 
the pattern of in vitro and in vivo glycosaminogly- 
can synthesis changes with age and degree of devel- 
opment. In the primate aorta, the amount of der- 
matan sulfate has been shown to increase with age 
with a concomitant decrease in chondroitin sulfate 
A  and/or C  (25,  53).  It  is  noteworthy  that  our 
arterial  smooth  muscle  cell cultures  were  estab- 
lished from  I-2-yr old monkeys and that the cells 
had been passed an average of three to four times. 
Thus, it is possible that dermatan sulfate synthesis 
by these cells may reflect an age-dependent (num- 
ber  of  cell  doublings)  biosynthetic  program  of 
these macromolecules (18).  It would be of interest 
to  compare  the  pattern  of  glycosaminoglycan 
synthesis by cultures established from embryonic 
aortas  with  that  observed  by  cells  from  older 
donors  or  cells that  had  gone  through  a  greater 
number of generations in culture. 
Toole and Lowther (61) have demonstrated that 
dermatan sulfate proteoglycan isolated from skin 
and  heart  valves  exhibits  the  ability  to  form 
precipitates  when  mixed  with  tropocollagen  at 
physiological pH and ionic strengths. These obser- 
vations have led to the suggestion that one possible 
function of dermatan sulfate is to participate in the 
formation and orientation of collagen fibrils. Pri- 
mate  arterial  smooth  muscle  cells do  synthesize 
and secrete collagen in vitro (J. Burke, unpublished 
observations) and it may be that  the synthesis of 
dermatan  sulfate  by these  cells is closely tied to 
collagen fibrillogenesis in these cultures. Collagen 
as  well  as  chondromucoprotein  are  known  to 
influence  the  synthesis of glycosaminoglycans by 
other cell types (20, 38, 39, 45). 
It is also possible that other types of cells present 
in  the  artery wall synthesize one  class of glycos- 
aminoglycan while the smooth muscle cells synthe- 
size  another.  Recent  experiments  have  demon- 
strated that cultured rabbit aortic endothelial cells 
form significant quantities ofchondroitin sulfate A 
and  considerably  less  dermatan  sulfate  (5).  It 
remains to be determined whether primate endo- 
thelial cells exhibit a similar pattern of glycosami- 
noglycan synthesis. 
To  our  knowledge,  the  only  other  cell  type 
known  to  synthesize  such  large  quantitites  of 
dermatan  sulfate  in  vitro  is  the  skin  fibroblast 
derived  from  patients  with  the  Hurler's  or 
Hunter's syndrome (33, 34). The large amount of 
dermatan sulfate associated with these fibroblasts 
has been shown to be due to the lack of turnover 
of this macromolecule by these cells since they do 
not produce the enzyme necessary to degrade der- 
matan  sulfate  (L-iduronidase) (1).  There  are  no 
data on the ability of arterial smooth muscle cells 
to  synthesize  glycosaminoglycan-degradative en- 
zymes  in  vitro.  In  contrast,  Hermein  et  al.  (17) 
recently demonstrated  that  dermatan  sulfate  ex- 
hibited the most rapid turnover of all of the gly- 
cosaminoglycans tested in the rat aorta, a species 
notably  resistant  to  atherosclerosis.  Thus,  even 
though  arterial  smooth  muscle  cells  synthesize 
large quantities of dermatan  sulfate, this macro- 
molecule may be degraded at a  rapid rate in non- 
injured  arteries,  preventing  its  accumulation. 
However, in species that are susceptible to lesion 
formation, dermatan sulfate may turn  over more 
slowly, explaining its accumulation in lesions such 
as  the  human  atherosclerotic  fatty  streaks  (27). 
There  are at present no data on the in vivo con- 
tent of glycosaminoglycans in the nonhuman  pri- 
mate artery (M. nemestrina).  Further studies are 
needed to determine whether differences in  turn- 
over of glycosaminoglycans are responsible for the 
differential accumulation of these macromolecules 
in the artery wall. 
The  function  of dermatan  sulfate in  the artery 
wall  needs  to  be  clarified.  Berenson  (2)  demon- 
strated that dermatan sulfate isolated from bovine 
aorta exhibits antithrombotic activity, as has been 
demonstrated  for  dermatan  sulfate  from  other 
sources  (15).  Thus,  one  possible function  of this 
macromolecule  in  the  artery  wall may  be  in  the 
prevention of thrombosis (11). 
The  importance  of  dermatan  sulfate  in  the 
artery wall has recently been emphasized by Ive- 
rius (22, 23) who has demonstrated that dermatan 
sulfate  exhibits  the  greatest  affinity for  binding 
with  low density lipoproteins at physiological pH 
and ionic strength of all of the glycosaminoglycans 
tested. His observations suggest a  role for derma- 
tan  sulfate  in  acting  as  a  trap  or  sink  for  lipid 
deposits that form in the lesions of atherosclerosis. 
Arterial Smooth Muscle vs. 
Dermal Fibroblasts 
Whatever the reason  for dermatan sulfate syn- 
thesis by primate arterial smooth  muscle cells in 
WIGHT AND ROSS  Proteoglycans  in Primate Arteries. II  683 vitro, this  pattern  of synthesis  is  clearly different 
from  that  exhibited  by  primate  skin  fibroblasts 
cultured  under  identical  conditions.  The  large 
amount  of  hyaluronic  acid  produced  by  dermal 
fibroblasts  in  this  study  is  consistent  with  other 
studies which have shown hyaluronic acid to be the 
major  glycosaminoglycan  synthesized  by cultures 
of various  types  of fibroblasts,  including  dermal 
fibroblasts (see, for reviews, references 40 and 42). 
The large amount of hyaluronic acid and the small 
amount  of dermatan  sulfate  produced  by dermal 
fibroblasts  contrast  sharply  with  the  arterial 
smooth  muscle cells which demonstrate  an  oppo- 
site pattern,  namely the formation  of large quan- 
tities  of  dermatan  sulfate  and  relatively  little 
hyaluronic  acid.  This  difference,  coupled  with 
other morphological differences in their pattern  of 
in vitro growth and in their fine structure, provides 
an additional means to discriminate between these 
two cell types in culture. 
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Note Added in Proof." Since the submission  of this pa- 
per, Radhakrishnamurthy  et al. (1975.  Composition of 
connective tissue  in aortas from rhesus  monkeys during 
regression  of diet-induced fatty streaks.  Lab. Invest. 33: 
136.)  have  demonstrated  that  dermatan  sulfate  is  the 
major aortic glycosaminoglycan present  in  the nonhu- 
man primate rhesus  monkey unlike other species where 
chondroitin sulfate A and/or C is the predominant aortic 
glycosaminoglycan.  These  findings  indicate  that  the 
large  amount  of dermatan  sulfate  synthesized  and  se- 
creted  by  cultured  nonhuman  primate  arterial  smooth 
muscle cells observed in  the present  study  may  reflect 
the pattern  of glycosaminoglycan synthesis  that  occurs 
in intact arteries of nonhuman primates. 
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